Caribou Biosciences, Inc. (NASDAQ:CRBU) Shares Bought by Exchange Traded Concepts LLC

Exchange Traded Concepts LLC lifted its stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) by 103.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 82,494 shares of the company’s stock after purchasing an additional 41,948 shares during the quarter. Exchange Traded Concepts LLC owned about 0.09% of Caribou Biosciences worth $162,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. AQR Capital Management LLC acquired a new stake in shares of Caribou Biosciences in the 2nd quarter worth approximately $30,000. Entropy Technologies LP acquired a new position in shares of Caribou Biosciences during the 1st quarter worth $113,000. Bayesian Capital Management LP purchased a new position in Caribou Biosciences during the 1st quarter valued at about $151,000. Walleye Trading LLC acquired a new position in Caribou Biosciences during the first quarter worth about $155,000. Finally, Point72 DIFC Ltd raised its position in Caribou Biosciences by 389.4% during the second quarter. Point72 DIFC Ltd now owns 30,157 shares of the company’s stock worth $49,000 after acquiring an additional 23,995 shares during the last quarter. Institutional investors and hedge funds own 77.51% of the company’s stock.

Caribou Biosciences Stock Performance

Shares of CRBU opened at $1.97 on Tuesday. The company has a market capitalization of $177.93 million, a price-to-earnings ratio of -1.36 and a beta of 2.27. Caribou Biosciences, Inc. has a 1 year low of $1.50 and a 1 year high of $8.33. The company’s 50 day simple moving average is $1.99 and its 200 day simple moving average is $2.46.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings data on Tuesday, August 6th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.04. The business had revenue of $3.46 million for the quarter, compared to analysts’ expectations of $3.31 million. Caribou Biosciences had a negative return on equity of 34.76% and a negative net margin of 372.78%. Equities analysts expect that Caribou Biosciences, Inc. will post -1.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on the stock. HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Caribou Biosciences in a research note on Tuesday, September 3rd. Royal Bank of Canada reissued an “outperform” rating and set a $14.00 price target on shares of Caribou Biosciences in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $11.25.

About Caribou Biosciences

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.